COMPOUNDS HAVING MUSCARINIC RECEPTOR AGONIST AND BETA-2-ADRENERGIC RECEPTOR AGONIST ACTIVITY

摘要

FIELD: chemistry.;SUBSTANCE: invention relates to organic chemistry and specifically to a compound of formula I ; and pharmaceutically acceptable salts and solvates thereof. In the compounds of formula I: Y is selected from Y2 and Y1, which are divalent groups of formula or , where A₁ and A₂ independently absent or selected from a group consisting of (C₁-C₁₂)alkylene, (C₃-C₈)cycloalkylene; B is absent or selected from a group consisting of phenylene, optionally substituted with one group selected (C₁-C₆)alkoxy; C is absent or selected from a group consisting of -O-, -N(R₇) - or represents one of the following groups C1-C2 , where R₇ in each case independently represents H or is selected from a group consisting of a straight or branched (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, phenyl, phenyl(C₁-C₆)alkyl, (C₁-C₈)alkylcarbonyl, (C₃-C₈)cycloalkylcarbonyl, phenylcarbonyl, (C₁-C₈)alkoxycarbonyl, (C₁-C₈)alkylaminocarbonyl, (C₁-C₁₀)alkylsulphanyl and phenylsulphonyl; and where R₇ can optionally be further substituted with one group selected from halogen, -CN, (C₁-C₈)alkyl, halogen (C₁-C₈)alkyl, phenyl, phenyl (C₁-C₆)alkyl, (C₁-C₈)alkoxy, phenyl(C₁-C₈)alkoxy, (C₃-C₈)cycloalkyl, which is a saturated monocyclic group, D is absent or is selected from a group consisting of (C₁-C₁₂)alkylene and phenylene; n, n', n'' and n''' in each case independently equal to 0 or integer from 1 to 3; E is absent or is selected from -O-, -NR₇-, -NR₇-C(O)-, -C(O)-NR₇-; G is absent or is phenylene or thienylene, optionally substituted with one or two substitutes selected from a group consisting of halogen atoms, (C₁-C₁₀)alkyl, phenyl, halophenyl, thienyl and (C₁-C₁₀)alkoxy; L is absent or is a divalent group selected from -C(O)-, (C₁-C₈)alkylcarbonylen and (C₂-C₈) alkenylcarbonylene; i is 1 or 2; i' is equal to 1 or 2; R₁ in each case is independently selected from hydrogen and halogen; s is equal to 0. Also disclosed are a pharmaceutical composition, use of the compound of formula I and a device.;EFFECT: technical result is obtaining novel compounds acting as both muscarinic receptor antagonists and beta-2-adrenergic receptor agonists.;14 cl, 2 tbl, 31 ex